Refine Your Search

  • Solutions

  • Therapeutic Areas

  • Resource Type

Assessing Drug-Smoking Interactions

Physiologically-based modeling and simulation helped a drug sponsor anticipate the impact of smoking cessation on drug exposure levels and toxicity risk.

Solution: PBPK Modeling & Simulation
Therapeutic Area: Central Nervous System
More Info

Physiologically-based Modeling Supports Drug Development Decisions, Regulatory Interactions and Drug Labeling

Today’s powerful and actively evolving computational tools enable sponsors and regulators to understand potential drug characteristics and subject responses earlier in development, with greater certainty. Model-based approaches support timely, confident decisions across the development and regulatory life cycle by gathering disparate sources of information about a drug, its competitors, target disease and patients into a […]

Solution: PBPK Modeling & Simulation
Therapeutic Area: Cardiovascular, Infectious Disease, Oncology/Hematology, Pediatrics
More Info

Getting at the HAART of Precision Dosing: Using PBPK Models to Optimize Dosing of an Antiviral

Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. It is primarily metabolized by CY2B6. A standard dose of efavirenz has been associated with serious adverse reactions in poor metabolizers (PMs) of CYP2B6, necessitating a reduction […]

Speaker(s): Manoranjenni Chetty
Solution: Model-informed Drug Development, PBPK Modeling & Simulation
Therapeutic Area: Infectious Disease
More Info
Learn More LinkedIn Twitter Facebook Email Subscribe to the Blog